<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02277119</url>
  </required_header>
  <id_info>
    <org_study_id>Maestro2</org_study_id>
    <nct_id>NCT02277119</nct_id>
  </id_info>
  <brief_title>Clinical Study of the Optic Disc Parameters</brief_title>
  <official_title>Topcon 3D OCT-1 Maestro Optic Disc and RNFL Study: Agreement and Repeatability Comparison With the iVue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Topcon Medical Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Topcon Medical Systems, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the repeatability and agreement of the Optic Disc Parameters, Retinal Nerve Fiber
      Layer (RNFL) Thickness, and Full Retinal Thickness between the Maestro and iVue OCT devices
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optic Disc Measurements (Optic Disc Size)</measure>
    <time_frame>1 Hour</time_frame>
    <description>Reporting of the Optic Disc Size difference between the Maestro and iVue</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinal Nerve Fiber Layer (RNFL) Thickness Measurements</measure>
    <time_frame>1 Hour</time_frame>
    <description>RNFL thickness measured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Full Retinal Thickness Measurement</measure>
    <time_frame>1 Hour</time_frame>
    <description>Full Retinal Thicknesses Measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Optic Disc Measurement (Cup Size)</measure>
    <time_frame>1 Hour</time_frame>
    <description>Reporting of the Cup size difference between the Maestro and iVue</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Normal Healthy Subjects With No Known Ocular Diseases</condition>
  <condition>Glaucomatous Eyes</condition>
  <condition>Eyes With Retinal Diseases</condition>
  <arm_group>
    <arm_group_label>Normal Eyes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with no known ocular diseases will be scanned with the iVue and Maestro device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glaucomatous Eyes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects presenting with different stages of glaucoma will be scanned with the iVue and Maestro device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eyes with Retinal Diseases</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects presenting with Retinal pathological eyes will be scanned on the iVue and Maestro device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Maestro</intervention_name>
    <description>OCT machines used for diagnostic purposes</description>
    <arm_group_label>Normal Eyes</arm_group_label>
    <arm_group_label>Glaucomatous Eyes</arm_group_label>
    <arm_group_label>Eyes with Retinal Diseases</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iVue</intervention_name>
    <description>OCT machines used for diagnostic purposes</description>
    <arm_group_label>Normal Eyes</arm_group_label>
    <arm_group_label>Glaucomatous Eyes</arm_group_label>
    <arm_group_label>Eyes with Retinal Diseases</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Normal Group

          1. Subjects 18 years of age or older on the date of informed consent

          2. Subjects able to understand the written informed consent and willing to participate as
             evidenced by signing the informed consent

          3. Subjects presenting at the site with normal eyes (eyes without pathology)

          4. lOPs 21mmHg bilaterally

          5. BCVA 20/40 or better (each eye)

          6. Both eyes must be free of eye disease

        Exclusion Criteria for Normal Group

          1. Subjects that have participated in any previous study using 3D OCT-1 Maestro device.

          2. Subjects unable to tolerate ophthalmic imaging

          3. Subject with ocular media not sufficiently clear to obtain acceptable OCT images

          4. HFA visual field (24-2 Sita Standard, white on white) result abnormal, defined as GHT
             'Outside Normal Limits' and/or PSD &lt; 5%

          5. HFA visual field (24-2 Sita Standard, white on white) result unreliable (based on
             manufacturer's recommendation), defined as fixation losses&gt; 33% or false positives &gt;
             25%, or false negatives &gt; 25%

          6. Presence of any ocular pathology except for cataract

          7. Previous ocular surgery or laser treatment, other than uncomplicated refractive
             procedure or cataract surgery, performed within six months prior to study scanning

          8. Narrow angle

          9. History of leukemia, dementia or multiple sclerosis

         10. Concomitant use of hydroxychloroquine and chloroquine

        Inclusion Criteria for Glaucoma Group

          1. Subjects 18 years of age or older on the date of informed consent

          2. Subjects able to understand the written informed consent and willing to participate as
             evidenced by signing the informed consent

          3. Subjects presenting at the site with glaucoma

          4. BCVA 20/40 or better in the study eye

          5. HFA visual field (24-2 Sita Standard, white on white) result abnormal, defined as GHT
             'Outside Normal Limits' and/or PSD &lt; 5% in the study eye

        Exclusion Criteria for Glaucoma Group

          1. Subjects that have participated in any previous study using 3D OCT-1 Maestro device.

          2. Subjects unable to tolerate ophthalmic imaging

          3. Subject with ocular media not sufficiently clear to obtain acceptable OCT images

          4. HFA visual field (24-2 Sita Standard, white on white) result unreliable, defined as
             fixation losses &gt; 33% or false positives &gt; 25%, or false negatives &gt; 25% in the study
             eye

          5. Presence of any ocular pathology except glaucoma in the study eye

          6. Previous ocular surgery or laser treatment, other than uncomplicated refractive
             procedure or cataract surgery, performed within six months prior to study scanning in
             the study eye

          7. History of leukemia, dementia or multiple sclerosis

          8. Concomitant use of hydroxychloroquine and chloroquine

        Inclusion Criteria for Retinal Group

          1. Subjects 18 years of age or older on the date of informed consent

          2. Subjects able to understand the written informed consent and willing to participate as
             evidenced by signing the informed consent

          3. Subjects presenting at the site with retinal disease

          4. lOP &lt;= 21mmHg in the study eye

          5. BCVA 20/400 or better in the study eye

          6. Diagnosis of some type of retinal pathology by investigator, may include, but not
             limited to: Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy,
             Macular Hole, Epiretinal Membrane, Cystoid Macula Edema, and others

        Exclusion Criteria for Retinal Group

          1. Subjects that have participated in any previous study using 3D OCT-1 Maestro device.

          2. Subjects unable to tolerate ophthalmic imaging

          3. Subject with ocular media not sufficiently clear to obtain acceptable OCT images

          4. Presence of glaucoma or any ocular pathology other than a Retinal pathology (e.g.,
             cornea pathology) in the study eye

          5. Previous ocular surgery or laser treatment other than uncomplicated refractive
             procedure or cataract surgery performed within six months prior to study scanning in
             the study eye

          6. Narrow angle in the study eye

          7. History of leukemia, dementia or multiple sclerosis

          8. Concomitant use of hydroxychloroquine and chloroquine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mike Sinai, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Topcon Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Western University of Health Sciences</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91716</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY College of Optometry</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2014</study_first_submitted>
  <study_first_submitted_qc>October 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2014</study_first_posted>
  <results_first_submitted>May 31, 2016</results_first_submitted>
  <results_first_submitted_qc>September 14, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 2, 2016</results_first_posted>
  <last_update_submitted>September 14, 2016</last_update_submitted>
  <last_update_submitted_qc>September 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Normal Eyes</title>
          <description>Subjects with no known ocular diseases will be scanned with the iVue and Maestro device
Maestro: OCT machines used for diagnostic purposes
iVue: OCT machines used for diagnostic purposes</description>
        </group>
        <group group_id="P2">
          <title>Glaucomatous Eyes</title>
          <description>Subjects presenting with different stages of glaucoma will be scanned with the iVue and Maestro device
Maestro: OCT machines used for diagnostic purposes
iVue: OCT machines used for diagnostic purposes</description>
        </group>
        <group group_id="P3">
          <title>Eyes With Retinal Diseases</title>
          <description>Subjects presenting with Retinal pathological eyes will be scanned on the iVue and Maestro device
Maestro: OCT machines used for diagnostic purposes
iVue: OCT machines used for diagnostic purposes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Normal Eyes</title>
          <description>Subjects with no known ocular diseases will be scanned with the iVue and Maestro device
Maestro: OCT machines used for diagnostic purposes
iVue: OCT machines used for diagnostic purposes</description>
        </group>
        <group group_id="B2">
          <title>Glaucomatous Eyes</title>
          <description>Subjects presenting with different stages of glaucoma will be scanned with the iVue and Maestro device
Maestro: OCT machines used for diagnostic purposes
iVue: OCT machines used for diagnostic purposes</description>
        </group>
        <group group_id="B3">
          <title>Eyes With Retinal Diseases</title>
          <description>Subjects presenting with Retinal pathological eyes will be scanned on the iVue and Maestro device
Maestro: OCT machines used for diagnostic purposes
iVue: OCT machines used for diagnostic purposes</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="27"/>
            <count group_id="B4" value="109"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.2" spread="13.3"/>
                    <measurement group_id="B2" value="57.8" spread="20.2"/>
                    <measurement group_id="B3" value="60.5" spread="13.4"/>
                    <measurement group_id="B4" value="48.7" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Optic Disc Area Difference</title>
          <units>Microns Squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.197" spread="0.228"/>
                    <measurement group_id="B2" value="0.201" spread="0.262"/>
                    <measurement group_id="B3" value="0.097" spread="0.216"/>
                    <measurement group_id="B4" value="0.165" spread="0.235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Optic Disc Measurements (Optic Disc Size)</title>
        <description>Reporting of the Optic Disc Size difference between the Maestro and iVue</description>
        <time_frame>1 Hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal Eyes</title>
            <description>Subjects with no known ocular diseases will be scanned with the iVue and Maestro device
Maestro: OCT machines used for diagnostic purposes
iVue: OCT machines used for diagnostic purposes</description>
          </group>
          <group group_id="O2">
            <title>Glaucomatous Eyes</title>
            <description>Subjects presenting with different stages of glaucoma will be scanned with the iVue and Maestro device
Maestro: OCT machines used for diagnostic purposes
iVue: OCT machines used for diagnostic purposes</description>
          </group>
          <group group_id="O3">
            <title>Eyes With Retinal Diseases</title>
            <description>Subjects presenting with Retinal pathological eyes will be scanned on the iVue and Maestro device
Maestro: OCT machines used for diagnostic purposes
iVue: OCT machines used for diagnostic purposes</description>
          </group>
        </group_list>
        <measure>
          <title>Optic Disc Measurements (Optic Disc Size)</title>
          <description>Reporting of the Optic Disc Size difference between the Maestro and iVue</description>
          <units>Mircrons squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.197" spread=".228"/>
                    <measurement group_id="O2" value="0.097" spread="0.216"/>
                    <measurement group_id="O3" value="0.201" spread="0.262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Retinal Nerve Fiber Layer (RNFL) Thickness Measurements</title>
        <description>RNFL thickness measured</description>
        <time_frame>1 Hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal Eyes</title>
            <description>Subjects with no known ocular diseases will be scanned with the iVue and Maestro device
Maestro: OCT machines used for diagnostic purposes
iVue: OCT machines used for diagnostic purposes</description>
          </group>
          <group group_id="O2">
            <title>Glaucomatous Eyes</title>
            <description>Subjects presenting with different stages of glaucoma will be scanned with the iVue and Maestro device
Maestro: OCT machines used for diagnostic purposes
iVue: OCT machines used for diagnostic purposes</description>
          </group>
          <group group_id="O3">
            <title>Eyes With Retinal Diseases</title>
            <description>Subjects presenting with Retinal pathological eyes will be scanned on the iVue and Maestro device
Maestro: OCT machines used for diagnostic purposes
iVue: OCT machines used for diagnostic purposes</description>
          </group>
        </group_list>
        <measure>
          <title>Retinal Nerve Fiber Layer (RNFL) Thickness Measurements</title>
          <description>RNFL thickness measured</description>
          <units>Microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.682" spread="4.333"/>
                    <measurement group_id="O2" value="2.526" spread="6.367"/>
                    <measurement group_id="O3" value="4.103" spread="8.789"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Full Retinal Thickness Measurement</title>
        <description>Full Retinal Thicknesses Measurement</description>
        <time_frame>1 Hour</time_frame>
        <population>Glaucomatous eyes were not scanned and analyzed in the Full Retina Thickness portion of the study. Since the imaging is done in a different area of the eye compare to Retinal Nerve Fiber Layer participants analyzed will be different between these measurement areas.</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Eyes</title>
            <description>Subjects with no known ocular diseases will be scanned with the iVue and Maestro device
Maestro: OCT machines used for diagnostic purposes
iVue: OCT machines used for diagnostic purposes</description>
          </group>
          <group group_id="O2">
            <title>Glaucomatous Eyes</title>
            <description>Subjects presenting with different stages of glaucoma will be scanned with the iVue and Maestro device
Maestro: OCT machines used for diagnostic purposes
iVue: OCT machines used for diagnostic purposes</description>
          </group>
          <group group_id="O3">
            <title>Eyes With Retinal Diseases</title>
            <description>Subjects presenting with Retinal pathological eyes will be scanned on the iVue and Maestro device
Maestro: OCT machines used for diagnostic purposes
iVue: OCT machines used for diagnostic purposes</description>
          </group>
        </group_list>
        <measure>
          <title>Full Retinal Thickness Measurement</title>
          <description>Full Retinal Thicknesses Measurement</description>
          <population>Glaucomatous eyes were not scanned and analyzed in the Full Retina Thickness portion of the study. Since the imaging is done in a different area of the eye compare to Retinal Nerve Fiber Layer participants analyzed will be different between these measurement areas.</population>
          <units>Microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.845" spread="11.482"/>
                    <measurement group_id="O3" value="21.299" spread="24.524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Optic Disc Measurement (Cup Size)</title>
        <description>Reporting of the Cup size difference between the Maestro and iVue</description>
        <time_frame>1 Hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal Eyes</title>
            <description>Subjects with no known ocular diseases will be scanned with the iVue and Maestro device
Maestro: OCT machines used for diagnostic purposes
iVue: OCT machines used for diagnostic purposes</description>
          </group>
          <group group_id="O2">
            <title>Glaucomatous Eyes</title>
            <description>Subjects presenting with different stages of glaucoma will be scanned with the iVue and Maestro device
Maestro: OCT machines used for diagnostic purposes
iVue: OCT machines used for diagnostic purposes</description>
          </group>
          <group group_id="O3">
            <title>Eyes With Retinal Diseases</title>
            <description>Subjects presenting with Retinal pathological eyes will be scanned on the iVue and Maestro device
Maestro: OCT machines used for diagnostic purposes
iVue: OCT machines used for diagnostic purposes</description>
          </group>
        </group_list>
        <measure>
          <title>Optic Disc Measurement (Cup Size)</title>
          <description>Reporting of the Cup size difference between the Maestro and iVue</description>
          <units>Microns cubed</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.072"/>
                    <measurement group_id="O2" value="-0.003" spread="0.124"/>
                    <measurement group_id="O3" value="0.016" spread="0.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Normal Eyes</title>
          <description>Subjects with no known ocular diseases will be scanned with the iVue and Maestro device
Maestro: OCT machines used for diagnostic purposes
iVue: OCT machines used for diagnostic purposes</description>
        </group>
        <group group_id="E2">
          <title>Glaucomatous Eyes</title>
          <description>Subjects presenting with different stages of glaucoma will be scanned with the iVue and Maestro device
Maestro: OCT machines used for diagnostic purposes
iVue: OCT machines used for diagnostic purposes</description>
        </group>
        <group group_id="E3">
          <title>Eyes With Retinal Diseases</title>
          <description>Subjects presenting with Retinal pathological eyes will be scanned on the iVue and Maestro device
Maestro: OCT machines used for diagnostic purposes
iVue: OCT machines used for diagnostic purposes</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Charles Reisman</name_or_title>
      <organization>Topcon</organization>
      <phone>201-599-5283</phone>
      <email>CREISMAN@topcon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

